Transforming cancer treatment with Protein Phosphatase 2A inhibitors
Investment Snapshot
Ticker: (NASDAQ:LIXT)
Stock Price
Accumulate $5
Winning Scenario
Over $20
Long Term Target*
$40-$50
*Long term is 2+ years
Short Term Target
$8-$10
Editors Note: The shares are oversold, continue trending in the plus $4 range, the wild swings down on the chart are likely shorts hunting stop losses. The Stock is a pressure cooker at these levels.
RISK: The stock is a box checker, low float, Cancer and well-funded, we also believe the short position is underreported. Easily over $20 with just a couple of the upcoming scenarios playing out.
Catalyst:
1B/2 Trial – Ovarian Clear Cell Cancer
LIXT is Teaming Up with the Top Oncology Players, including a Global Pharma Giant that could soon be Eyeballing a Huge Buyout!
LIXTE Biotechnology (NASDAQ:LIXT) holds the world’s only clinical-stage PP2A inhibitor, with Phase 1b/2 trial results on the horizon, and is protected by long-term patents
- Cancer breakthrough tech: LB-100 helps existing drugs find missed tumors.
- Big Pharma backing: Trials with GSK at MD Anderson and Northwestern, .
- Huge gap in pricing: $35-45 probability-weighted value vs. ~$4 today.
- Massive market: Oncology projected to reach $530B by 2032.
- Patient benefit: Reducing toxic doses keeps more patients on treatment. (TXT BOX)
- Technical Analysis: Simply stated, LIXT has a sweet stock setup.
Dear Undervalued Pharma Seekers,
Readers who took quick action on stocks that I recently covered, could have locked in profits from 70%, and counting, to 900%, but when promising Biopharmaceutical companies work, the returns often dwarf that.
LIXTE is positioned to deliver a potential once in a lifetime Cancer protocol platform win for patients and investors. My research and the charts tell me smart investors should buy (NASDAQ:LIXT) up to at least the $8-10 range, soaking up the low hanging shares and let it play out. If LIXTE’s lead compound, LB-100, hits on its ongoing trial, the results could literally be life changing.
Make no mistake, I only cover companies that I believe you, and other readers, have a great chance to get in before the trading masses, algos, and institutions are able to send shares soaring on expected upcoming news announcements.
These small caps move quick, so, if you wait to learn about (LIXT) when news breaks, you’ll miss a big part of the move.
The catalyst is coming soon, so I’m sharing some of the information you need to get ahead of them. The float is under 5 million shares, which means that the stock will likely move quickly on any positive news from the upcoming clinical trial results.
So, taking a position anywhere below the $10 mark should allow investors to sell into the teens on positive cancer trial updates.
LIXT Bayesian Valuation Snapshot
This probability-weighted valuation model highlights the asymmetric upside of LIXTE’s LB-100. Using conservative assumptions and indication-level success probabilities:
The Bayesian Valuation Snapshot is built by modeling LB-100’s ongoing OCCC trials; across low, mid, and high success scenarios.
Each scenario assumes different clinical success probabilities, comparable oncology licensing revenue potential, and standard biotech economics, like royalty-equivalent values and risk discounting.
The failure case, if trial fails and LB-100 has no path forward , yields $6-7/share. The base case is probability- adjusted value, at $35-45/share, and the high case, strong efficacy, reaches $75-100/share.
By weighting these outcomes with industry-standard Phase 2 oncology success probabilities and adjusting for timelines and risk, the model produces a probability-weighted valuation of $35-45/share, about 10× above today’s price. In short, this framework captures both the risk of trial failure and the asymmetric upside if one indication hits, showing why LB-100 represents such a powerful risk/reward setup.
- Failure Case: 0 value beyond cash/IP floor ($6–7/share).
- Base Case (PWV): $35–45/share (probability-adjusted value if OCCC hits).
- High Case: $75–100/share if efficacy is strong enough to justify accelerated adoption or label expansion.
This is why Recent cancer news set (NASDAQ:LIXT) Soaring from $0.30 to a high of more than $5.
LB-100 recently cleared its first safety hurdle, with a favorable toxicity profile, and LIXT is now advancing an active Phase 1b/2 trial for LB-100 in combination with an established cancer therapy and partnered with leading organizations.
In ovarian clear-cell carcinoma, LB-100 is being tested with GlaxoSmithKline or GSK’s checkpoint inhibitor at MD Anderson and Northwestern University, with interim data expected in Q4 2025.
With multiple Phase 1b/2 trial results on the horizon, LIXTE’s (LIXT) collaborations are set to deliver multiple clinical updates in the coming months and offer compelling catalysts.
In addition to these trials, the Inland Cancer Institute published groundbreaking data in AACR’s Cancer Discovery showing LB-100 causes “lethal activation”; overdriving colon cancer cells until they collapse in cell death. This is a powerful new therapeutic strategy and LIXTE is ahead of everyone else in applying it clinically.
Nature Reviews validated this breakthrough in its “Too Much of a Good Thing” editorial.
Big Pharma Validation
GSK plc (NYSE:GSK) isn’t just a partner, they’re one of the largest cancer drug companies in the world, with a multi-billion-dollar oncology portfolio and global market leadership.
Catalyst
- Q3/Q4 2025 – Ovarian Clear Cell interim readout with GSK’s checkpoint inhibitor.
Without a doubt, LXTE is an explosive biopharma play, with a strong risk reward proposition that could mean losing all the chips on the table. However, some of the planet’s smartest money in this space, GSK, is funding the trial and they’re in the business to win. In fact, it’s not a stretch to think that they could be looking at LIXT as an acquisition target.
LIXTE’s President is a Biotechnology Executive who not only oversaw numerous clinical trials from start to publication, he co-founded a company that was acquired by a leading Nasdaq genomics company and then helped lead another company to partner with this same $15+ billion leader in a pact to sell diagnostic tests to its clients, so he obviously knows how to structure deals.
Of course, $15 billion is tiny compared to GSK, but even on the bigger deals the fundamentals are the key to success.
Unlike a single-use drug, LB-100 has the potential to function as a platform technology, enhancing the power of existing therapies while allowing for lower, less toxic doses. That combination could keep more patients on treatment longer, addressing the reality that up to 59% of cancer patients discontinue therapy due to side effects. With patents extending into the 2040s, partnerships with global leaders like GSK , and applicability across multiple cancer types, LB-100 is positioned not just to change treatment protocols, but to impact millions of lives worldwide, while opening the door to multi-billion-dollar licensing and royalty streams in a projected $530-billion oncology market
LB‑100 has been under scientific evaluation for nearly a decade, with its first human safety and tolerability study published in Clinical Cancer Research in 2017, marking the beginning of its translation from bench to bedside. Since then, research into LB‑100 has grown significantly: the compound’s mechanism and preclinical efficacy are detailed in over 25 peer-reviewed publications, spanning studies on chemotherapy synergy, immunotherapy enhancement, glioblastoma models, and neoantigen generation (NASDAQ:LIXT).
LIXT’s chart shows it’s consolidating; with major support over $3 & less than 5M shares in the float, this is set up for a space launch.
The Most Asymmetric Trade in Cancer Right Now: (NASDAQ:LIXT)
First-in-class. No competition. Huge partners. And still under $5.
LIXTE Biotechnology quietly holds the only clinical-stage PP2A inhibitor in the world, LB-100, a potential a cancer power-up that supercharges existing cancer therapies to find hidden tumors, reduce toxicity, and enhance immune response.
LB-100 is a first-in-class molecule that disables cancer’s repair system and lights up tumors to the immune system.
When LB-100 is active tumors can’t fix themselves, the immune system finally sees the cancer, and other treatments become more effective; at better doses, which translates into fewer side effects, fewer dropouts, and more survivors.
The BOTTOM Line
The bottom line is this: everything you’ve just read points to LB-100’s efficacy and mechanisms are supported by 25+ publications, major academic centers, and Global leaders like MD Anderson, NKI, Northwestern, City of Hope, multiple imminent trial readouts, and a market valuation that doesn’t yet reflect its potential. There’s far more to uncover, so don’t stop here. Go to LIXTE’s website, read their press releases, watch their videos, and dig into independent due diligence. When you see the science, the partnerships, and the timing lined up the way they are now, I believe you’ll see exactly what I see; a rare, high conviction opportunity that may not come around again.
We’ve had a strong run of winners this past year and NASDAQ:LIXT has all the hallmarks of another one.
That said, biotech is a high-volatility sector and even the most promising stories can hit unexpected setbacks, so set limits, monitor company news closely, and manage risk by limiting your exposure to what you can afford. However, as you know, setups like this don’t come often. LIXTE owns a first-in-class, IP-protected molecule, partnered with heavyweight partners, including some of the biggest names in oncology, and is heading into a massive near-term catalyst; all while trading at a valuation that barely reflects their last funding round.
Good Luck,
Editor
Do yourself a favor and sign up to receive breaking news Alerts so you don’t miss out on updates about LIXTE Biotechnology.
DISCLOSURE: 24/7 Market News Inc. (247), owns and operates 247marketnews.com is a third-party publisher and news release service provider which disseminates corporate news electronically through multiple online media platforms. 247 is NOT an affiliate with any of the companies mentioned in our reports. 247 is a news distribution service and is not registered with FINRA or any other professional licensing service. 247 is not an analyst, broker dealer or advisor, and holds no such licenses. 247 may NOT offer to buy, sell, or hold any security. 247 Venture Beats, and Breakfast bits and any other corporate profiles will NEVER be a solicitation or recommendation of any kind, of any security mentioned. The materials in all our releases are intended to be for informational purposes only and should never be considered research or due diligence on any company mentioned. All readers are encouraged to perform standard due diligence by reading the company’s filings at SEC.gov. Readers should consult their broker or licensed professional before investing in any company. All materials in this release are based on publicly available statements made by the companies. 247 is not liable for any investment decisions made by any readers or subscribers. Any investment could result in you losing all your money from investing in any stock. 247’s editor owns no shares of Lixtie Biotechnology Holdings Inc., LIXT and will not trade in the stock. Publisher has been paid for ongoing investor outreach, and news coverage by Microcap strategy on behalf of the company of up to twenty-five thousand dollars a week for the next three months. 24/7 will also be using financial marketing tools to engage with the investment community online. Editors are paid to put a best-case scenario profile out to the investing public. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements.
All information, opinions, analyses, technical analysis, trading price targets, and support and resistance interpretations presented in this publication represent the author’s personal views and are fully protected under the First Amendment of the United States Constitution. The content provided herein is intended solely as editorial opinion, general market commentary, or educational material, and should never be construed as financial or investment advice. This publication does not constitute a solicitation or recommendation to buy or sell securities, commodities, or any other financial instruments. Readers are strongly advised to conduct their own independent research or seek professional advice before making any investment decisions. For additional information regarding First Amendment protections for financial newsletters and commentary, please refer to Lowe v. SEC, 472 U.S. 181 (1985): https://supreme.justia.com/cases/federal/us/472/181/
Copyright © 2025 24/7 MarketNews